Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Morphosys
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Novartis
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Nurix
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pharmacyclics
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Sanofi
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    SeaGen
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Takeda
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    TG Therapeutics
    Topic:
    honorarium/consulting
    Date added:
    05/05/2023
    Date updated:
    08/02/2024

Pages

Return to 2024 Seattle Cellular Therapy Summit: Updates and Focus on Accessibility